Skip to Main Content
1
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 1st, suite A
New Haven, CT 06511
1 of 2
  • Smilow Cancer Hospital at Yale New Haven
    35 Park Street, Fl 1st, suite A
    New Haven, CT 06511
  • Smilow Cancer Hospital Care Center at Greenwich
    77 Lafayette Place
    Greenwich, CT 06830

Mariya Rozenblit, MD

Medical Oncology
Telehealth is available
Learn more about telehealth
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Internal Medicine

Biography

Mariya Rozenblit, MD, is a medical oncologist who specializes in treating patients with different types of breast cancer, from ductal carcinoma in situ (DCIS), the most common type of breast cancer, to metastatic breast cancer, or stage IV breast cancer.

Dr. Rozenblit research focuses on biomarker-driven trial development in breast cancer. These types of clinical trials allow researchers to investigate how patients (including those with different cancer mutations) respond to available medications. For example, Dr. Rozenblit co-authored a study that found patients younger than 40 with advanced breast cancer often suffer a worse prognosis and more severe symptoms than older patients.

She has received the American Society of Clinical Oncology’s Conquer Cancer Foundation’s Young Investigator Award and the Susan G. Komen Cancer Catalyst Research Grant. Dr. Rozenblit is an assistant professor of medicine (medical oncology) at Yale School of Medicine.

Titles

  • Assistant Professor of Medicine (Medical Oncology)

Education & Training

  • Internal Medicine Resident
    NYU Langone Medical Center (2018)
  • MD
    Icahn School of Medicine at Mount Sinai (2015)
  • BA
    Columbia University, Biology (2009)

Additional Information

Biography

Mariya Rozenblit, MD, is a medical oncologist who specializes in treating patients with different types of breast cancer, from ductal carcinoma in situ (DCIS), the most common type of breast cancer, to metastatic breast cancer, or stage IV breast cancer.

Dr. Rozenblit research focuses on biomarker-driven trial development in breast cancer. These types of clinical trials allow researchers to investigate how patients (including those with different cancer mutations) respond to available medications. For example, Dr. Rozenblit co-authored a study that found patients younger than 40 with advanced breast cancer often suffer a worse prognosis and more severe symptoms than older patients.

She has received the American Society of Clinical Oncology’s Conquer Cancer Foundation’s Young Investigator Award and the Susan G. Komen Cancer Catalyst Research Grant. Dr. Rozenblit is an assistant professor of medicine (medical oncology) at Yale School of Medicine.

Titles

  • Assistant Professor of Medicine (Medical Oncology)

Education & Training

  • Internal Medicine Resident
    NYU Langone Medical Center (2018)
  • MD
    Icahn School of Medicine at Mount Sinai (2015)
  • BA
    Columbia University, Biology (2009)

Additional Information

1
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 1st, suite A
New Haven, CT 06511
1 of 2
  • Smilow Cancer Hospital at Yale New Haven
    35 Park Street, Fl 1st, suite A
    New Haven, CT 06511
  • Smilow Cancer Hospital Care Center at Greenwich
    77 Lafayette Place
    Greenwich, CT 06830